Newton, MA – Labshares, a leading provider of shared laboratory facilities and a collaborative hub for emerging biotech companies, has announced several key achievements from 2024. Despite the difficult funding environment for biotech companies, Labshares’ accomplishments underscore its position as the leader in providing emerging biotechs with capital-efficient shared lab solutions.

‍

Strong Growth Outpaces the Industry 

• Expanding Membership: Labshares welcomed 10 new companies in 2024, achieving a year-end occupancy rate of over 80%. During a time when many incubators and lab spaces are challenged to attract new customers, Labshares' capital-efficient model continues to flourish.
• Winning New Types of Customers: In 2024, Labshares attracted several new members who transitioned from large leased or subleased lab spaces. Recognizing the benefits of Labshares' capital-efficient model, these members chose to leave their self-managed facilities in favor of Labshares comprehensive ecosystem.
• World-Class VCs Backing Labshares Members: Member companies attracted funding from top-tier venture capital firms such as ARCH, Atlas Ventures, Bain Capital, and Frazier Healthcare, reflecting the high degree of innovation found within the Labshares ecosystem.

‍

Expanded Value Proposition Leads to Record Customer Satisfaction

In 2024, Labshares members gained access to new lab equipment valued at roughly $2 million, including multiple new flow cytometers, a cell sorter, a cell dispenser, advanced automation equipment, next-gen electroporators, multiplexed immunoassays, and advanced PCR capabilities.

‍

Labshares’ members also benefited from and expanded its services in 2024, including two new vivarium partnerships, in-house rDNA permitting (the only incubator / shared lab to have this), and enhanced safety training. These offerings streamline research processes and improve regulatory compliance for members.

‍

The above improvements solidify Labshares' position as the ideal home for biotechs, enabling members to reduce capital spend, lower operational costs, gain more flexible terms, and ultimately lower their risk as compared to managing independent facilities.These improvements—along with Labshares’ scientifically-oriented staff—resulted in a November 2024 member survey with 80% of members giving Labshares the highest possible customer satisfaction score, the best result in the company’s history. 

‍

Growing Team

In May 2024, Labshares welcomed Devon Lagasse as its new Vice President of Growth. With experience at MSD and Eppendorf, Devon brings scientific and workflow expertise to support biotech companies. She adds to a deep team with decades of biotech and life science experience.

‍

Significant New Partnership with Thermo Fisher Scientific

In December, Labshares signed a five-year agreement with Thermo Fisher Scientific to provide on-site support, OEM maintenance, and access to cutting-edge technologies. This partnership highlights Labshares’ dedication to supporting biotech innovation.

‍

Looking Ahead to 2025

Labshares enters 2025 with a refreshed online presence, including customer experience videos and a redesigned website, showcasing its offerings and dynamic community. Labshares is poised for another year of growth and innovation, further solidifying its role as the premier choice for emerging biotechs.

‍

For more information, visit www.labshares.com.

‍